Martin Babler

Mr. Babler is President and Chief Executive Officer of Principia Biopharma, Inc. (NASDAQ: PRNB). In August 2020, Principia and Sanofi entered into a definitive acquisition agreement valued at approximately $3.7 billion. Mr. Babler previously served as President and Chief Executive Officer of Talima Therapeutics from 2007 to 2011. Prior to this, Mr. Babler was a senior executive at Genentech including Vice President, Immunology Sales and Marketing. During his time at Genentech, he oversaw the Commercial Development organization and led the Cardiovascular Marketing organization.Mr. Babler began his pharmaceutical industry career at Eli Lilly and Company. He holds a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich. Mr. Babler graduated from the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.